Top Markets
Coin of the day
Myovant Sciences Ltd. Myovant Sciences Ltd.

Myovant Sciences Ltd.

MYOV
Rank in Stocks #5525
Myovant Sciences Ltd. is a biopharmaceutical company focused on innovating... Myovant Sciences Ltd. is a biopharmaceutical company focused on innovating healthcare solutions for both women and men. Its flagship product is relugolix, an orally administered, once-daily small molecule that functions as a gonadotropin-releasing hormone (GnRH) receptor antagonist. This medication is indicated for conditions such as heavy menstrual bleeding caused by uterine fibroids, pain associated with endometriosis, and advanced prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin agonist, currently in Phase II clinical trials for treating female infertility within assisted reproductive procedures. Myovant collaborates with Pfizer Inc. for the development and commercialization of relugolix across oncology and women's health sectors. Incorporated in 2016, initially as Roivant Endocrinology Ltd. before rebranding to Myovant Sciences Ltd. in May of that year, the firm is based in London, United Kingdom, and operates as a subsidiary of Sumitovant Biopharma Ltd.
Share Price
$26.98
Last synced: 2023-03-09
Market Cap
$2.62B
Change (1 day)
-0.04%
Change (1 year)
0.00%
Country
GB
Trade Myovant Sciences Ltd. (MYOV)

Category

Stock price history for Myovant Sciences Ltd. (MYOV)
Highest end of day price: $26.97 on 2023-03-01

Lowest end of day price: $12.79 on 2016-10-01
Stock price history of Myovant Sciences Ltd. from 2016 to 2026
Annual Stock Price Performance
Year Performance
2023 0.28%
2022 73.07%
2021 -37.07%
2020 50.47%
2019 -4.83%
2018 41.15%
2017 8.58%
2016 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$549.38 41.20%
US
$1.05K 47.75%
NL
$148.35 491.02%
US
$122.63 -12.65%
AU
$760.57 6.54%
CH